Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.
A research team from the University of Michigan Medical School, USA, developed a supplementary intranasal treatment to improve COVID-19 vaccine response and its effects on long-lasting immunity from other variants, such as the B.1.351 variant first found in South Africa.
A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.
Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Financial toxicity among breast cancer patients is independently associated with worse psychological well-being following a mastectomy or lumpectomy operation.
Researchers from the Department of Critical Care Medicine, Sichuan Provincial People's Hospital, Chengdu in China, have explored the possibility of using hydrogen therapy on severely ill COVID-19 patients. The team published their study's findings, titled "Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients," in the latest issue of the journal Frontiers in Pharmacology.
New results presented at the 12th European Breast Cancer Conference show that a test, which looks at the activity of 70 genes in breast cancer tissue, is possible to use in the clinic to identify patients with invasive lobular carcinoma (ILC) that is at high risk of recurring and progressing.
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
Lung cancer is the second most common cancer in both men and women in the United States. It is also the leading cause of cancer death among both sexes, making up nearly 25% of all cancer deaths nationwide.
Melanoma is a malignant tumour resulting from the transformation of melanocytes, the cells in the skin that undertake to synthesise melanin, a complex polymer which protects us from the negative effects of solar radiation.
The final results of the randomized phase two trial E3311 will be presented at the American Society of Clinical Oncology annual meeting, to occur virtually from May 29-31.
HPV-negative UM-SCC4 with and without transfection of HPV E6 oncoprotein, HPV-negative UPCI-SCC-089, and HPV-positive UPCI-SCC-099 cell lines were used in this study.
The cover for issue 10 of Oncotarget features Figure 3, "Overall survival (OS) for high (red) versus low (black) risk groups in the (A) OSU, (B) TCGA, and (C) SNU resected cohorts," by Wolfe, et al.
Scientists at Case Western Reserve University are using Artificial Intelligence (AI) to reveal apparent cellular distinctions between black and white cancer patients, while also exploring potential racial bias in the rapidly developing field of AI.
A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment.
Radionuclide therapy has proven successful in delaying the growth of disseminated tumor cells (DTCs) in early-stage breast cancer in a small animal model, suggesting its use as a potential adjuvant therapy for retarding the proliferation of DTCs.
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.
A new clinical trial at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute aims to reduce malnutrition among patients with lung cancer by offering nutritional counseling and medically tailored meals to at-risk patients.
A new type of blood test for breast cancer could help avoid thousands of unnecessary surgeries and otherwise precisely monitor disease progression, according to a study led by the Translational Genomics Research Institute and Mayo Clinic in Arizona.
Advanced colon cancer often spreads widely and may not respond to standard chemotherapy. In such a case, a novel combination of drugs and flexible dosing may help achieve a better outlook, as demonstrated by several new studies.